Dr. Kim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2312 N Nevada Ave
Ste 400
Colorado Springs, CO 80907Phone+1 719-577-2555Fax+1 719-577-2553
Summary
- M.D., University of Arizona, College of Medicine; B.S. in Biochemistry, University of Arizona; Hematology-Oncology Fellowship, Emory University School of Medicine; Hematology Fellowship, Harbor-UCLA Medical Center; Internal Medicine Residency, Harbor-UCLA Medical Center.
Dr. Kim is committed to research and for the last five years has served as the principal investigator for the Eastern Cooperative Oncology Group at the Oncology Institute of Greater Lafayette.
Education & Training
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 1996 - 1998
Los Angeles County-Harbor-UCLA Medical Center 1Fellowship, Hematology and Medical Oncology, 1995 - 1996- Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1992 - 1995
University of Arizona College of MedicineClass of 1992
Certifications & Licensure
CA State Medical License 1993 - Present
CO State Medical License 2003 - 2025
GA State Medical License 1996 - 1999- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases Start of enrollment: 2011 Dec 01
- TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis Start of enrollment: 2009 Mar 01
- Analysis of Percutaneous Ablations for Cancer Treatment Start of enrollment: 2012 Feb 01
Publications & Presentations
PubMed
- 54 citationsHistone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.Zachary L. Watson, Tomomi M. Yamamoto, Alexandra McMellen, Hyunmin Kim, Connor J. Hughes
Clinical Epigenetics. 2019-11-27 - 48 citationsPU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stressJames S. Chavez, Jennifer L. Rabe, Dirk Loeffler, Kelly C. Higa, Giovanny Hernandez
The Journal of Experimental Medicine. 2021-06-07 - 23 citationsMulti-Omic Approaches Identify Metabolic and Autophagy Regulators Important in Ovarian Cancer DisseminationLindsay J. Wheeler, Zachary L. Watson, Lubna Qamar, Tomomi M. Yamamoto, Brandon T. Sawyer
Iscience. 2019-09-27
Other Languages
- Korean
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
